135 related articles for article (PubMed ID: 15467258)
1. [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset].
Ojima K; Kiyono Y; Kojima M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):245-55. PubMed ID: 15467258
[TBL] [Abstract][Full Text] [Related]
2. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
[TBL] [Abstract][Full Text] [Related]
3. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
4. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
Mori Y; Ojima K; Fuujimori Y; Aoyagi I; Kusama H; Yamazaki Y; Kojima M; Shibata N; Itoh Y; Tajima N
Endocrine; 2006 Apr; 29(2):309-15. PubMed ID: 16785606
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Malaisse WJ
Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
[TBL] [Abstract][Full Text] [Related]
6. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients.
Malaisse WJ
Expert Opin Pharmacother; 2008 Oct; 9(15):2691-8. PubMed ID: 18803455
[TBL] [Abstract][Full Text] [Related]
7. [Effects of mitiglinide in treatment of impaired glucose tolerance].
Katahira H; Ishida H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():444-50. PubMed ID: 15779420
[No Abstract] [Full Text] [Related]
8. Mitiglinide: KAD 1229, S 21403.
Drugs R D; 2004; 5(2):98-101. PubMed ID: 15293870
[TBL] [Abstract][Full Text] [Related]
9. Mitiglinide for type 2 diabetes treatment.
Phillippe HM; Wargo KA
Expert Opin Pharmacother; 2013 Oct; 14(15):2133-44. PubMed ID: 23992284
[TBL] [Abstract][Full Text] [Related]
10. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
[TBL] [Abstract][Full Text] [Related]
11. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
Ohkura T; Inoue K; Fujioka Y; Nakanishi R; Shiochi H; Sumi K; Yamamoto N; Matsuzawa K; Izawa S; Ohkura H; Kato M; Yamamoto K; Taniguchi S
BMC Res Notes; 2013 Nov; 6():453. PubMed ID: 24215809
[TBL] [Abstract][Full Text] [Related]
12. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
13. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
Endocr J; 2010; 57(7):579-86. PubMed ID: 20467165
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
17. Imaging docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules.
Nagamatsu S; Ohara-Imaizumi M; Nakamichi Y; Kikuta T; Nishiwaki C
Diabetes; 2006 Oct; 55(10):2819-25. PubMed ID: 17003348
[TBL] [Abstract][Full Text] [Related]
18. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel.
Reimann F; Proks P; Ashcroft FM
Br J Pharmacol; 2001 Apr; 132(7):1542-8. PubMed ID: 11264248
[TBL] [Abstract][Full Text] [Related]
19. Effects of combination of mitiglinide with various oral antidiabetic drugs in streptozotocin-nicotinamide-induced type 2 diabetic rats and Zucker fatty rats.
Akahane K; Ojima K; Yokoyama A; Inoue T; Kiguchi S; Tatemichi S; Takeda H; Imai Y
Clin Exp Pharmacol Physiol; 2017 Dec; 44(12):1263-1271. PubMed ID: 28744906
[TBL] [Abstract][Full Text] [Related]
20. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Pratley RE; Foley JE; Dunning BE
Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
